Partners Capital Investment Group, LLP Exelixis, Inc. Transaction History

Partners Capital Investment Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$18.93 - $24.75 $52,966 - $69,250	-2,798 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $5.09 Million - $6.42 Million	-259,441 Reduced 98.93%	2,798 $67,000
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $1.69 Million - $2.7 Million	123,993 Added 89.69%	262,239 $5.16 Million
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $283,279 - $399,840	17,850 Added 14.83%	138,246 $2.45 Million
Q2 2018 Aug 13, 2018	BUY	$18.56 - $22.45 $463,424 - $560,554	24,969 Added 26.17%	120,396 $2.59 Million
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $1.16 Million - $1.66 Million	52,190 Added 120.71%	95,427 $2.11 Million
Q4 2017 Feb 13, 2018	BUY	$24.23 - $30.93 $1.05 Million - $1.34 Million	43,237	43,237 $1.31 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Partners Capital Investment Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Partners Capital Investment Group, LLP with notifications on news.